Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Key Inclusion Criteria:

- Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal
cancer

- Complete or partial response following standard of care surgery and first line
chemotherapy

- May have one disease recurrence with complete or partial response or stable disease
following standard of care second line care treatment

- Previous investigational biologic therapy allowed, must be more than 56 days prior to
first injection

- Previous treatment with bisphosphonate allowed, must be completed 14 days prior to
first injection

- Ambulatory with an ECOG 0-1

- Life expectancy > 6 months

- Meet protocol-specified lab requirements

- Provide informed consent and have ability to comply with protocol requirements

Key Exclusion Criteria:

- Concurrent chemotherapy, radiation therapy, immunotherapy are excluded (washout
periods as specified in protocol)

- Prior receipt of survivin based vaccines

- Participation in prior therapeutic adjuvant ovarian cancer studies, except for
platinum-based adjuvant studies

- Progressive disease (rising CA-125 acceptable)

- More than one course of chemotherapy for recurrent disease

- Concurrent bevacizumab as maintenance therapy

- Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma
in situ, or controlled bladder cancer

- History of autoimmune disease

- Recent history of thyroiditis

- Presence of a serious acute infection or chronic infection

- Brain metastases

- Other serious intercurrent chronic or acute illness

- Ongoing treatment with steroid therapy or other immunosuppressive

- Acute or chronic skin disorders